Announcement on Foreign Investment of Subsidiary Peak Pharmaceutical
Release time:
2020-08-05
证券代码：600668 证券简称：尖峰集团 公告编号：临2018-002
债券简称：13尖峰01 债券代码：122227
债券简称：13尖峰02 债券代码：122344
浙江尖峰集团股份有限公司
关于子公司尖峰药业对外投资的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示：
l 交易简要内容：本公司控股子公司浙江尖峰药业有限公司（以下简称：尖峰药业）拟投资11132.79万元以收购股份和增资的方式对上海北卡医药技术有限公司（以下简称：上海北卡）进行投资。投资完成后，上海北卡注册资本由原来的1100万元增加至1755.55万元，其中尖峰药业占55%。
l 本次交易不构成关联交易
l 本次交易不构成重大资产重组
l 本次股权收购和增资事项经公司董事会审议后无需提交股东大会审议批准。
一、对外投资概述
（一）2018年1月19日，本公司控股子公司浙江尖峰药业有限公司和康立涛、李倩、郑亚玲、海南寰太生物医药产业创业投资基金合伙企业、上海北卡签订了《关于上海北卡医药技术有限公司之增资和股权转让协议》，尖峰药业拟投资11132.79万元以收购股份和增资的方式对上海北卡医药技术有限公司（以下简称：上海北卡）进行投资。投资完成后，上海北卡注册资本由原来的1100万元增加至1755.55万元，其中尖峰药业占55%。尖峰药业将以上海北卡及其子公司为平台建立原料药及中间体的研发、生产基地。
（二）董事会审议情况
2018年1月19日，公司以通信方式召开了第十届董事会第二次会议，公司现有九名董事，全部参加了会议，经审议与表决，董事会以9票同意、0票反对、0票弃权审议并通过了该事项。独立董事发表了独立意见。
（三）根据上海证券交易所《股票上市规则》和公司《章程》等有关规定，公司本次对外投资属董事会权限范围，无需提交股东大会审议。该合作事项不属于关联交易，也不构成《上市公司重大资产重组管理办法》规定的重大资产重组情况。
二、交易对方的基本情况
（一）康立涛，男，中国国籍，住址：上海市松江区影佳路***弄***号，职业：上海北卡董事长。
（二）李倩，女，中国国籍，住址：上海市浦东新区益丰路**弄***室，职业：上海北卡总经理。
（三）郑亚玲，女，中国国籍，住址：重庆市渝中区建兴坡***号，职业：重庆金赛医药有限公司董事长。
（四）海南寰太生物医药产业创业投资基金合伙企业
1、企业名称：海南寰太生物医药产业创业投资基金合伙企业（有限合伙）
2、企业性质：有限合伙企业
3、注册地：海口市龙华区国贸大道56号北京大厦21层C、D
4、注册日期：2015年02月11日
5、主要办公地点：海口市龙华区国贸大道56号北京大厦21层C、D
6、执行事务合伙人：海南寰太股权投资基金管理有限公司
7、经营范围：创业投资业务，创业投资咨询业务，为创业企业提供创业管理服务业务。
三、交易标的基本情况
（一）标的公司的基本情况
1、企业名称：上海北卡医药技术有限公司
2、企业性质：有限责任公司(国内合资)
3、注册地：上海市松江区申港路3802号21幢
4、注册日期：2003年10月20日
5、主要办公地点：上海市松江区申港路3802号21幢
6、法定代表人：康立涛
7、注册资本：1100万元
8、经营范围：医药和化学专业技术领域内的技术开发、技术咨询、技术服务、技术转让；机械设备、仪器仪表、食用农产品（不含生猪产品）、化肥、饲料添加剂、化工原料及产品（除危险品）批发零售；医药中间体的开发、销售；从事货物及技术的进出口业务。（依法须经批准的项目，经相关部门批准后方可开展经营活动）
9、主要股东：
|
序号 |
股东名称 |
出资额（万元） |
出资比例（%） |
|
1 |
康立涛 |
493.26 |
44.8418 |
|
2 |
李倩 |
306.74 |
27.8855 |
|
3 |
郑亚玲 |
200 |
18.1818 |
|
4 |
海南寰太生物医药产业创业投资基金合伙企业 |
100 |
9.0909 |
|
|
合计 |
1100 |
100 |
10、业务情况
上海北卡是上海市高新技术企业，上海市“专精特新”科技企业、“上海市专利试点企业”，建有院士专家工作站和松江区“企业技术中心”，有多项 “上海市高新技术成果转化项目”成果，曾荣获“上海市松江区科技进步二等奖”等。上海北卡有较强的研发能力，已获得14项专利。其总部设在上海市松江区申港路3802号“新飞企业家园”内，租有三栋独立的厂房用于研发和办公，合计面积1787.91平方米。目前主要业务为国内外制药企业提供产品和定制服务，产品主要包括替尼类、生物碱类、糖类等抗肿瘤药物中间体等，定制服务主要是新药和中间体的CDMO（合约开发制造）。
上海北卡拥有两家全资子公司，安徽常泰化工有限公司（以下简称：常泰化工）和安徽北卡医药有限公司（以下简称：安徽北卡）。
常泰化工是工信部定点的农药生产企业，是上海北卡通过收购获得的全资子公司，成立于2007年7月，注册资本3000万元，经营范围：间苯氧基苯基氰基甲醇、一甲胺盐酸盐、2-氯-5-氯甲基吡啶、啶虫脒原药、联苯菊酯原药、虱螨脲原药、农药制剂的水剂、乳油类制剂、微乳剂、可湿性粉剂、盐酸厄洛替尼、吉非替尼、达沙替尼及以上药物的中间体的开发、生产、销售；20%亚磷酸、乙醇、甲醇、甲苯、环己烷、N,N-二甲基甲酰胺（DMF）、丙烯腈、40%一甲胺水溶液，生产、销售；化工原料及产品（不含危化品）的批发、零售。住所：安徽省池州市东至县香隅镇化工园区。占地78,351.51平方米，现拥有三个化学合成车间和一个农药制剂复配车间，拥有10个产品批文,13项专利。常泰化工将在现有业务的基础上，进一步向医药中间体方向延伸。
安徽北卡成立于2016年12月，注册资本1000万元，经营范围：化学原料药和医药中间体的定制、生产和销售，化工原料及产品的批发和零售（危化品除外）；生物技术，新型化合物药物、活性成分药物及药用化合物的技术开发、咨询、服务和转让。住所：安徽东至经济开发区。安徽北卡还获批承担安徽省重大新兴产业工程项目“小分子靶向药物制造基地”，将建设成以医药原料药为主的生产基地，以承接上海北卡的成果转化。
（二）标的公司2016年和2017年合并财务报表情况
截至2017年末，上海北卡合并资产总额8990.76万元、负债总额7452.97万元、归属于母公司股东权益1537.79万元；2017年合并营业收入8490.31万元、归属于母公司所有者净利润-652.55万元；截至2016年末，上海北卡合并资产总额8852.27万元、负债总额5423.27万元、归属于母公司股东权益2294.23万元。2016年度合并营业收入7056.74万元、归属于母公司所有者净利润-203.18万元。
2016年度的财务数据经具有证券、期货从业资格的毕马威华振会计师事务所（特殊普通合伙）审计，2017年度的财务数据未经审计。
（三）交易标的评估情况
本次交易委托具有证券从业资格的坤元资产评估有限公司对上海北卡股东的全部权益价值进行评估。坤元资产评估有限公司所出具了《资产评估报告》（坤元评报〔2017〕1-37号），上海北卡股东的全部权益价值评估价值为12280.19万元，评估基准日为2017年9月30日。
评估公司本次评估分别以资产基础法和收益法进行了评估，由于资产基础法固有的特性，资产基础法中无法单独考虑企业的人力资源、客户资源、管理内控水平、要素协同等因素对企业价值的影响，其评估结果未能涵盖企业的全部资产的价值，且资产基础法以企业单项资产的再取得成本为出发点，有忽视企业的获利能力的可能性，由此导致资产基础法与收益法两种方法下的评估结果产生差异。根据北卡医药公司所处行业和经营特点，收益法评估价值能比较客观、全面地反映目前企业的股东全部权益价值。
因此，本次评估最终采用收益法评估结果122,801,900.00元（大写为人民币壹亿贰仟贰佰捌拾万壹仟玖佰元整）作为北卡医药公司股东全部权益的评估值。
（四）上海北卡最近一次增资的情况。
2016年10月，上海北卡曾进行增资，注册资本从1000万元增加到1100万元，海南寰太出资人民币1000万元，其中：100万元记入注册资本，900万元记入资本公积。
（五） 权属状况说明
交易对方所持的上海北卡股权产权清晰，不存在抵押、质押情况，不涉及诉讼、仲裁事项或查封、冻结等司法措施。
四、协议的主要内容
2018年1月19日，尖峰药业（甲方或“投资方”）和原股东康立涛、李倩、郑亚玲、海南寰太生物医药产业创业投资基金合伙企业（合称乙方）、上海北卡（丙方或标的公司）签订了《关于上海北卡医药技术有限公司之增资和股权转让协议》。协议的主要内容有：
（一）增资和股权转让
1.1各方同意，甲方为本次交易的唯一股权受让方和增资方，本次股权转让出资额310万元和全部新增股权出资额655.55万元均由投资方受让和认缴。交易价格以评估值为基础，各方协商确定。标的公司股东全部权益作价12680万元，每股（元）转让和增资价格均为11.53元，甲方总投资金额为11132.79万元（其中：股权转让款为3574.30万元、增资款为7558.49万元，若有扣除金额则相应减少股权转让款）。
1.1.1原股东康立涛本次出让股权74.00万，股权转让款为853.22万元；
原股东李倩本次出让股权46.00万，股权转让款为530.38万元；
原股东郑亚玲本次出让股权90万，股权转让款为1037.70万元；
原股东海南寰太本次出让股权100万，股权转让款为1153万元。
1.1.2甲方出资7558.49万元，认缴本次标的公司新增注册资本655.55万元。
1.1.3甲方投资完成后，标的公司注册资本增加655.55万元，即注册资本由原1100万元增至1755.55万元。其中：甲方占55%、康立涛占23.88%、李倩占14.85%、郑亚玲占6.27%。
1.2股权转让款的分期支付及分期增资
协议各方一致同意按以下方式，由甲方按股权比例向乙方分别支付股权转让款，并在满足每期相关条件后的15工作日内支付：
1.2.1第一期支付金额为原股东康立涛、李倩、郑亚玲股权转让款的30%、原股东海南寰太股权转让款的100%，总计1879.39万元。应满足以下付款条件：
具备本协议生效条件，本协议生效。
1.2.2第二期支付金额为原股东康立涛、李倩、郑亚玲股权转让款的50%，总计1210.65万元。应满足以下付款条件，
1.2.2.1 协议各方签署《交接协议》，协议各方完成交接，并不存在交接不清、影响日后工作的事项。
1.2.2.2完成股权转让的工商变更登记，达到权利方能合法行使股权。
1.2.3第三期支付金额为减去“扣除金额”后剩余的股权转让款项，应满足以下付款条件：
1.2.3.1甲方在《交接协议》签订一年内，且乙方已履行本协议项下的全部义务，分两次支付给乙方。
1.2.3.2 提供足额完税证明。
若出现“扣除金额”的情形，甲方或标的公司可通过下列途径要求乙方承担或追偿垫付的款项和利息损失：①从应付原个人股东的股权转让款项中扣除，或②原个人股东直接承担或向甲方、标的公司偿还，或③从原个人股东以后公司分红款中扣回或划付，或④通过法律渠道向原个人股东追偿。
1.2.4甲方支付乙方股权转让款到指定的原股东的银行帐户、账号。
1.2.5各方同意，本协议生效后15日内支付第一期增资款4612万元（对应出资额400万元）；剩余增资款2946.49万元（对应出资额255.55万元）在本协议生效后半年内出资到位。
1.3各方同意，投资方应将本协议约定的各期投资金额按约定条件，以现金方式付至公司账户或股东账户。
1.3.1在本协议约定的全部条件满足后，标的公司、股权转让方应按照本协议约定向投资方提供董事会决议、股东会决议、修改后的公司章程或章程修正案、股权转让协议（每次/每人）等文件正本并获得投资方的书面认可。
1.3.2投资方在收到本协议相应条款所述文件/条件后15个工作日内支付当期投资价款。如果投资方未按照本条的规定及时支付当期投资价款，则投资方应当就迟延支付部分的金额按银行同期贷款利率计算的利息向标的公司和/或原股东支付逾期缴付的违约金。如投资方未在本协议约定的各期投资应到位日后的15日内支付当期投资价款，则标的公司和/或原股东有权解除本协议。
1.4 投资方成为公司股东后，依照法律、本协议和公司章程的规定享有所有股东权利并承担相应股东义务，公司的资本公积金、盈余公积金和未分配利润由投资方和公司原股东按本协议确定的股权比例享有。
1.5各方同意，投资方对标的公司的全部出资不得用于委托贷款和委托理财等风险投资。
1.6本合同约定的第一期增资款到位并办理交接手续后3个月内，标的公司应向原股东清偿所有股东借款（431.3万元）。
1.7双方同意，在本协议签订后变更标的公司章程，在遵守《公司法》、《会计准则》及上市公司监管要求，并且保证正常生产经营的前提下，原则上标的公司每年现金分红比例不少于当年实现的可分配利润的30%（全体股东另行达成一致的情况除外）。
1.8未来股权安排
1.8.1原个人股东承诺，除非本协议另有约定或协议各方达成一致，自本次转让增资的工商变更登记手续完成后八年内不转让其所有持的标的公司股权，也不得在其股权上设置任何质押、担保等权利负担。八年后若原个人股东拟出让其股权，须符合法律法规、上市公司监管要求，并在标的公司（合并报表）每年扣非后净利润不低于3000万元，或三年累计扣非后净利润不低于9000万元的前提下（提出转让提案前三年），各方可协商甲方或第三方以现金或其他合法方式分批收购原个人股东持有的标的公司股权；甲方或第三方应在不晚于原个人股东向甲方提出转让提案后的三年内完成对原个人股东持有的全部股权的收购。
1.8.2收购价格应按市场价格确定或以双方共同认可的评估值为基础且不低于标的公司净资产的基础上协商确定。
1.9在合作期间，如协议各方向非同一实际控制人的第三方出让标的公司股权，应保证受让方按同等条件收购协议其他方所持有的全部股权。
（二）变更登记手续与交接
2.1各方同意，在本协议生效、甲方支付第一期股权转让款和第一期增资款后15个工作日内，由标的公司负责完成工商登记变更手续(包括但不限于按本协议修改并签署的公司章程及按本协议规定选举的董事、监事等在登记机关的变更备案)。
2.2如果公司未按时办理登记变更手续，且逾期超过30天仍无法办理相应的变更登记手续(由于政府方面原因或不可抗力的因素情形除外)，投资方有权以书面通知的形式提出终止本协议，公司和/或原股东应于本协议终止后15个工作日内退还投资方已经支付的全部投资价款（包括股权转让款和增资款），并支付违约金（按该笔款项银行同期贷款利率计算）。但如果投资方同意豁免的情形除外。
2.3办理变更登记或备案手续所需费用由标的公司承担。
2.4交接
2.4.1协议各方同意在本协议生效15个工作日内，甲方派员与乙方在其经营场所进行交接，乙方应保证上述接收人员的进入，并协助接收人员对本协议规定的全部资产、资料进行清点，确保交接的顺利完成，接收人员对所接收的资产、资料等审核确认后，进行妥善置放。
（三）公司治理
3.1各方同意并保证，投资完成后，标的公司董事会成员五人，甲方提名三人、原股东提名二人担任标的公司董事；公司的董事长、法定代表人由投资方提名的董事担任。标的公司应在办理营业执照变更的同时办理董事变更手续。标的公司新董事会至少每半年召开一次董事会会议。标的公司设监事会，监事成员三人，甲方提名二人、原股东提名一人；公司监事会主席由投资方提名的监事担任。
3.2各方同意并保证，所有标的公司董事、监事和高级管理人员的任职资格均应当符合有关法律法规的规定。当上述任何一方提名的董事、监事辞任或者被解除职务时，由提名该董事、监事的一方继续提名继任人选，各方并应保证在相关公司权力机构上投票赞成该等人士担任公司董事、监事。
3.3公司总经理、副总经理、财务总监等高级管理人员由董事会聘任，高级管理人员的薪酬由董事会决定。公司应按照《公司法》、上市公司监管要求不断完善公司治理、完善财务等内控制度，并尽快建立对核心团队成员的激励制度。
（四）清算财产的分配
各方同意，如公司清算，先按所有股东实际投入现金比例进行分配，超出各股东的实际投入现金以上部分再按照股份比例分配。
（五）债务和或有债务
5.1原控股股东及公司承诺并保证，除已向投资方披露之外，公司并未签署任何对外担保性文件，亦不存在任何其他未披露的债务。如标的公司还存在未反映在公司财务报表中的或未披露的或有负债或者其他债务，全部由原股东和原控股股东承担。若公司先行承担并清偿上述债务，因此给公司造成损失，原控股股东和原股东应当在公司实际发生损失后5个工作日内，向公司全额赔偿，原控股股东和原股东应以其股权转让款，或从公司取得的分红，或从其他合法渠道筹措的资金履行赔偿义务。
（六）协议生效及其他
6.1除非本协议另有规定，各方应自行支付其各自与本协议及本协议述及的文件的谈判、起草、签署和执行的有关成本和费用。有关公司增资审批、审计、工商变更登记等费用由公司自行承担。本次交易中所涉及的税费，由各方根据相关法律的规定缴纳。
6.2 本协议在下述条件获得完全满足时生效：
6.2.1本协议由各方法定代表人或授权代表签字并加盖公章。
6.2.2本协议获得各方有权机构的正式批准。
6.3履行本协议时，各方将在此基础上签署工商登记所需的相关增资协议、公司章程、股权转让协议及其他必要文件。
五、本次合作对公司的影响及风险提示
（一）本次合作是根据公司“合作创新强主业、规范科学求发展”战略方针，加强医药业务板块发展的重要举措，如果该项合作能顺利完成，上海北卡及其子公司将成为尖峰药业的控股子公司，尖峰药业将以上海北卡及其子公司为平台建立原料药及中间体的研发、生产基地，进一步延伸并完善医药业务的产业链，有利于增加公司的医药产业规模，有利于提高尖峰药业的研发能力，有利于加强尖峰药业原料药生产保障，有利于提升尖峰药业的综合实力。
（二）本次对外投资的资金来源为公司的自有资金。
（三）本次对外投资对公司当期利润不会造成重大影响。
（四）风险提示：该项目投资的风险主要包括市场风险、技术风险、政策风险等。市场风险：受近年来化工原材料价格上升、能源成本增加、环保投入逐渐加大、市场价格不断变化等因素的影响，未来原料药品市场竞争形势存在一定的不确定性。技术风险：若标的公司所采用技术的先进性、可靠性、适用性和可行性与实际情况发生重大变化，将可能导致生产能力利用率降低，生产成本增加，产能达不到预期要求。政策风险：由于税收、环保、产业政策等的不断调整，将使税率、利率、环保要求等发生变化，将可能导致标的公司原定目标难以实现。
公司将根据合作事项的进度及时披露后续进展情况，敬请广大投资者注意投资风险。
特此公告
浙江尖峰集团股份有限公司
董事会
二〇一八年一月一十九日
More information
Group Party Committee Held Democratic Life Meeting
On February 7, the party Committee of the group company held the 2020 democratic life meeting to listen to the suggestions and opinions of grass-roots organizations and carry out criticism and self-criticism. The party committee members and senior executives of the participating groups reported on the annual evaluation of the company's management cadres, and studied personnel adjustment plans for some subordinate companies; listened to the opinions and suggestions of grassroots organizations and young employees, and scientific and technological personnel seminars, and focused on employees. Research and determine solutions to practical problems such as strengthening the management and distribution of labor protection supplies, increasing the quality control of labor protection supplies, increasing training related to new technologies and new businesses, and optimizing corporate university courses. The party committee members also carried out criticism and self-criticism together, analyzed and investigated their own problems, and put forward opinions and suggestions. (Reporter Ni Yingzhen)
2021
03-01
At the Jinhua City "Four Tackling Four Striving for the First" mobilization meeting held on February 18, Jianfeng Pharmaceutical won the honorary title of "Jinhua City's Top Ten Innovative Enterprises. The meeting mainly summarized the results of the "nine hard battles", studied and deployed the "four tackling and four striving for the first" action, further mobilized the whole city to further improve the style of work, work hard, and strive for the first place, so as to promote the "14th Five-Year Plan" to make a good start and start well. Step, celebrate the 100 anniversary of the founding of the party with outstanding results. In recent years, Jianfeng Pharmaceutical has relied on scientific and technological innovation to actively build a high-end preparation manufacturing platform, layout of high-end varieties in the pharmaceutical industry, and has achieved good results in improving scientific and technological innovation capabilities, promoting the transformation of scientific research results, deepening industry-university-research cooperation, and company talent training. Achievement. For the enterprise sustained, healthy and rapid development to provide strong support. (Zhu Ningyan)
2021
03-01
The first product of Erying Company goes on sale.
At the beginning of the new year, good news came from Zhejiang Erying Pharmaceutical Co., Ltd., a subsidiary of Jianfeng Pharmaceutical Co., Ltd., that the first product of the company since its establishment, Erying Baby Butt Care Ointment, successfully passed the examination and approval of Zhejiang Drug Administration and was officially listed. Erying Company is a joint venture formed by Jianfeng Pharmaceutical and German scientific research forces, focusing on the research and development, introduction, production and sales of pediatric drugs and skin care products. The "Baby Baby" series of products introduces German technology. The first product is Baby Baby Baby Butt Care Ointment, which mainly contains black seed oil, castor oil and sesame oil. Among them, black seed oil is rich in riquinone, black seed quinone and thyme quinone, which has the effects of antibacterial, anti-inflammatory, antioxidant and scavenging free radicals. Sesame oil is rich in vitamin C, vitamin E, vitamin A, fatty acids, minerals and various trace elements, which play a role in strong antioxidant activity, increasing skin luster and accelerating skin metabolism. Castor oil is a traditional medicine applied to burns and scabies. A variety of vegetable oil mixture has the effect of moisturizing and locking water, and is a natural skin deep "moisturizer". Compared with similar products on the market, Erying Baby Butt Care Ointment does not contain any hormones, preservatives, alcohol, pigments, flavors, talcum powder and other additives. It has unique vegetable oil fragrance and is mild in nature. It is very suitable for use on delicate skin of newborns to prevent the occurrence of red buttocks of newborns. (Gold Crystal)
2021
03-01
Group Companies Commend 2020 Advanced
On the afternoon of February 3, the group company held the 2020 annual summary commendation meeting to review the work of the previous year, make arrangements for the work of 2021, sign the 2021 economic responsibility system with various professional companies and directly affiliated enterprises, and solemnly commend the 2020 advanced collectives and individuals. In the past 2020, the sudden outbreak of new crown pneumonia has brought about tremendous changes in the lifestyle of the public and the business environment of enterprises, and has brought unprecedented challenges to the industrial sectors of the peak. In this context, the company has carried out various operation and management work in an orderly manner around the general policy of "making up for shortcomings, improving quality and efficiency, and creating core competitive advantages", overcoming various difficulties, and basically completing the work established at the beginning of the year. target. At the summary and commendation meeting, Yu Jianhong, general manager of the group company, made a work report entitled "following the law, reforming and innovating, and promoting better and faster development of peaks", which actively responded to the new coronary pneumonia epidemic and ensured the safety and health of all employees. Substantial progress has been made in the construction of key investment projects. Continuously strengthen management integration and effectively improve management level; New achievements have been made in scientific and technological innovation and technological transformation. Overcome the impact of the epidemic situation and strive to expand sales; innovate the forms of personnel training, selection and introduction, optimize the salary system and improve the cohesion of enterprises. New achievements have been made in safety and environmental protection management. Strengthen party building, ideological and political work and corporate culture to enhance the cohesion and centripetal force of enterprises; Nine aspects, including effective promotion of corporate image, influence and reputation, have made a comprehensive summary and review of the work in 2020. 2021 is the first year of the "14th Five-Year Plan" and the 100 anniversary of the founding of the Communist Party of China. It is a year of special importance in the process of China's modernization. However, there are many uncertainties in the development of the epidemic and changes in the external environment, the foundation of China's economic recovery is not yet solid, the world economic situation is still complex and severe, the recovery is unstable and unbalanced, and the various derivative risks caused by the impact of the epidemic cannot be ignored. In combination with the spirit of the 2021 Central Economic Work Conference, after a comprehensive analysis of the current national economic situation, policies and the changing trends of the company's related industries, Yu Jianhong, on behalf of the group company, proposed the 2021 work policy as "following the law, keeping the right and bringing forth the new, reforming and innovating, and continuously improving", and around this policy, proposed the key work for 2021: following the market law and trend, achieving the "five persistence", fundamentally reverse the ideological concepts of management cadres; do a good job in project management, cultivate industrial advantages, and steadily promote development; optimize the management system, strengthen management improvement, and improve management efficiency; further strengthen technological innovation, increase investment in technological transformation, and promote "digital intelligence" Factory "construction; respect market laws, pay attention to user needs, and improve marketing capabilities; do a good job in management team building to further strengthen human resource development; promote safety and environmental protection management to a new level; take party building as a guide, strengthen ideological and political work, enrich the connotation of corporate culture, and create" soft power "for enterprise competition; continue to grasp the normal management of the prevention and control of the new coronary pneumonia epidemic to ensure that all work can be carried out smoothly. Yu Jianhong pointed out that on the road of creating a century-old peak, we will face twists and turns, risks and challenges at any time. In the face of many tests, we will never be able to solve the problem, and hope can only rest on ourselves. In 2021, the peak will also face more severe challenges. With a conscientious style, a spirit of perseverance, and unswerving perseverance, we must unite and forge ahead, innovate the old, and work hard to create a brighter future for the peak cause. At the meeting, Yu Jianhong, on behalf of the group company, signed the 2021 economic responsibility system with Daye Peak, Yunnan Peak, Pharmaceutical Company, Health Technology Company, International Trading Company and Cable Company. Huang Jinlong, deputy general manager of the group company and chairman of Shanghai North Carolina Company, signed a responsibility system with the management team on behalf of the Shanghai North Carolina board of directors. Xiang Chongping, deputy general manager of the group company, read out the list of advanced collectives and advanced individuals of the group company in 2020 at the conference. In 2020, a total of 20 advanced collectives such as advanced enterprises, advanced civilized workshops (departments and offices), advanced party organizations, and 25 outstanding individuals such as outstanding employees, innovative experts, outstanding management workers, and outstanding marketers were selected, and outstanding party workers, 24 advanced individuals such as outstanding party members, outstanding party members, outstanding trade union workers, advanced safety and environmental protection workers, and rookie employees were selected. In the warm atmosphere, the advanced representative of the gold enterprise took the stage to receive the award. Zhou Jiping, former general manager of Yunnan Jianfeng, on behalf of advanced enterprises, was at the meeting site. Dong Li, representative of Anhui New Jianfeng North Card, and Wu Lihua, representative of Guizhou Huang Ping Jianfeng, an innovative expert, spoke via video respectively, reviewing the gains and losses of the past year's work and sharing experiences and experiences. On behalf of the party committee and board of directors of the group, Jiang Xiaomeng, secretary of the party committee and chairman of the group, congratulated the advanced collectives and individuals who were commended, thanked all the peak employees for their hard work and achievements, and made a summary speech entitled "seize the day for development, and improve the ability without delay" in view of the market situation and existing problems faced by the company that year (details are published separately in this edition). (this newspaper reporter)
2021
02-10
New Year Message Zhejiang Jianfeng Group Co., Ltd. Party Secretary, Chairman of Jianfeng Group All colleagues of Jianfeng Group: The law returns to the spring, and Vientiane is renewed. Unconsciously, the unforgettable Year of the Gengzi Rat has become a thing of the past, and the New Year of the Year of the Ox is coming to us in great strides. On behalf of the group company, I would like to express my sincere greetings to all the cadres and employees who have worked hard and dedicated for a year. The past year has been an extraordinary year. The sudden neo-coronary pneumonia epidemic has put the global economy and our country through an unprecedented and complex test. This year, we accurately studied and judged the epidemic situation, formulated and implemented various epidemic prevention and control measures as soon as possible, strengthened the publicity of epidemic prevention and control knowledge, organized and prepared epidemic prevention materials, strengthened the dynamic management of employees' health, and actively organized the resumption of work and production. Effectively curbed the adverse effects of the epidemic on production and operation; while doing a good job in internal epidemic prevention and control, it also donated money and materials to the government, charity, medical institutions, it has made a positive contribution to the joint force "war epidemic. During this period, no one in the whole group was infected, and the most severe period of the epidemic was safe and healthy. This year, we shouldered the extraordinary responsibility during the extraordinary period, made prudent and decisive scientific decisions, gathered the wisdom of all staff to overcome difficulties, and made obvious progress in market expansion, technological transformation, cost control, safety and environmental protection. This year, we paid close attention to the construction of the project. Guizhou Huangping Jianfeng Cement Project was successfully completed and put into production and reached the production standard. The internationalization project of Jianfeng Pharmaceutical, the technological transformation project of Anhui Xinbeika and the new warehouse project of Jianfeng International Trading Company are progressing in an orderly manner. New development projects are also being actively sought and discussed. This year, we strengthened the management and control of business risks, carried out in-depth optimization of institutions and positions, and vigorously promoted standardized and standardized management, and the operational efficiency of enterprises was significantly improved. This year, we innovated the forms of talent training, selection and introduction, optimized the salary system, worked hard to do a good job in corporate culture, and enhanced the cohesion and centripetal force of the enterprise. In this year, we have successively won a series of honors, such as "China's top 100 cement clinker production enterprises", "China's top 100 building materials enterprises", "excellent unit of corporate culture brand construction" in Zhejiang Province, "National May 4th Red Flag Youth League Committee", "China's top 500 enterprise credit", "top 100 pharmaceutical industry enterprises" and "top 50 creative enterprises" in Jinhua City, The corporate image and influence have been greatly improved. This year, we encountered many unprecedented difficulties and made more efforts than in previous years. The staff of pharmaceutical companies and large pharmacies are still organizing epidemic prevention materials on New Year's Eve. The backbone of Daye Peak drove "retrograde" thousands of miles back to their posts to organize epidemic prevention and maintenance. In order to put into production early and seize the market, the cadres and employees are engaged in equipment debugging regardless of day and night during equipment debugging and trial production... There are many flash moments, which are worth remembering forever. All the achievements of this year are the result of the hard work and sweat of the company's employees. They are the result of all the peak people expressing their responsibilities, creating achievements with hard work, hard work, wisdom and hard work. Here, on behalf of the group company, I would like to express my heartfelt thanks to all the cadres and employees of the peak and say to you: everyone is working hard! The new year brings new hope and new challenges. 2021 is the first year to implement the "14th Five-Year Plan" and start a new journey of building a modern socialist country in an all-round way. It is also the 100 anniversary of the founding of the Communist Party of China. At present, China is facing a great change not seen in a century, the world pattern is also undergoing great changes, the global epidemic of new crown pneumonia epidemic to accelerate the evolution of this great change. We should be soberly aware that all the existing glory on our report card has become the past, and the future of the peak will meet all kinds of known and unknown risks and challenges, and the grand blueprint of "creating a century-old peak" also requires every peak person to show greater drive, make more efforts, and show unyielding "bull strength" and conscientious "bull spirit", write a more beautiful chapter together. As the saying goes, a year's plan lies in spring. Spring represents the vitality, represents the hope, but also represents the future. At this peaceful and festive moment, let's wish all peak cadres and employees a happy New Year, good health, happy family and all the best!
2021
02-10
As the Spring Festival is approaching, Cai Yan, secretary of the Wucheng District CPC Committee of Jinhua City, visited Jianfeng on January 19 to express condolences to Jiang Xiaomeng, a top-notch talent in Jinhua City and chairman of the group company, and extended festive wishes and greetings to him. I would also like to express my gratitude to Jianfeng for his contribution to Jinhua's economic and social development. Jiang Xiaomeng and Cai Yan exchanged views on the future construction of the ecological corridor in central Zhejiang, the expansion and extension of the Jin Yi Kechuang corridor, and the development direction of biotechnology and medical device industry. They also introduced the new products of the peak pharmaceutical sector and invited her to visit the company's production line. At present, the domestic new coronary pneumonia epidemic has repeated, Jinhua is also strengthening prevention and control efforts, Cai Yan in particular for the peak in the early 2020 epidemic, Wucheng District epidemic prevention work is the most difficult, the most severe situation in a timely manner to lend a helping hand, donated forehead temperature guns, disinfectant, masks and other epidemic prevention materials, to medical institutions to donate money and materials to express gratitude. Cai Yan fully affirmed the business performance and development trend of Jianfeng Group in recent years, and highly praised Jianfeng people's pragmatic and innovative business attitude. She said that the pro-Qing political and business relations formed by Jianfeng Group and various units of the Wucheng District Government over the years have not come easily. She hopes that the two sides will further strengthen exchanges, and the government and enterprises will work together to create a good business environment. The Spring Festival is approaching. I wish Jianfeng will develop to a higher level in the new year, "just like your name", pursuing to rise to the top and constantly climb the peak. (Reporter Chen Shengmu)
2021
01-21
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page